Author

Danielle E. Hammond

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-6017-2264Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Sanam LoghaviiD· 2 shared Anna MalovannayaiD· 1 shared Antrix JainiD· 1 shared Branko CuglievaniD· 1 shared Christine E. Birdwell· 1 shared Christopher Peter MilliD· 1 shared Courtney Denton DinardoiD· 1 shared Feiyang MaiD· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Sanam LoghaviORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyBloodPeer-reviewedMar 4, 2024

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

Warren C. Fiskus, Jessica C. Piel, Michael P. Collins…·Kapil N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

49 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 28, 2023

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

Vera Ademà, Irene Gañán‐Gómez, Feiyang Ma…·Simona Colla

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

1 citation

humanclinical cohort / trial

𝕏 PostBluesky